ArticleStem cell research & therapy2025
Human embryonic stem cell-derived Sertoli cells as an immune modulator of cell transplantation therapy in a diabetic mice model.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Chondrocytes in fracture healing: A review of chondrocyte journey.Chinese medical journal · 2026Review
- Multimodal electroconductive PLGA-based scaffold orchestrates neuroprotection and regeneration following severe spinal cord injury.Journal of nanobiotechnology · 2026Article
- Antidiabetic agents and male fertility: unraveling the impact of glucose-lowering therapies on sperm quality in diabetic males-a narrative review.Translational andrology and urology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveSertoli cells (SCs) are somatic cells that are a part of the seminiferous tubules in the testes and support germ cell development and maturation. Additionally, SCs play another role in protecting male germ cells from immune destruction via the formation of the blood-testis barrier and the secretion of several immunoregulatory factors. Based on these characteristics, SCs have been suggested to create a tolerogenic environment to protect co-transplanted cells as immune modulators. Because mature SCs are quiescent somatic cells and show lower proliferation activity in vitro, it is difficult to obtain the number of human cells needed for clinical applications. MATERIALS AND
methodsWe established a protocol for mass production of SCs from human ESCs (hESC-SCs) and their functional properties were analyzed in vitro and in diabetic-induced mice after their co-transplantation with human insulin-secreting cells.
resultshESC-SCs were successfully produced via a stepwise differentiation protocol. In addition, a mass culture method was established to secure the number of hESC-SCs available for cell therapy. hESC-SCs obtained from in vitro derivation highly express marker genes of SCs, such as GATA4, SOX9, CLDN11, and AR, and have shown immune-modulation activity similar to that of human bone marrow-mesenchymal stem cells. In diabetic-induced mice subcutaneously co-transplanted with EndoC-βH1 cells (insulin-secreting cells) and hESC-SCs, lower blood glucose levels were maintained for 6 months than in those transplanted with EndoC-βH1 cells alone.
conclusionsWe believe that hESC-SCs could be useful tool for securing cell therapy to treat human diseases in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.